Clinical Trials Logo

Clinical Trial Summary

Nowadays, headache has been considered as one of the top global disabling medical conditions.1 Migraine is an important type of headache, and one of the chronic multifaceted neuro-inflammatory disorders.2 It is characterized by recurrent throbbing headache pain that typically affects one side of the head, and is often accompanied by nausea and disturbed vision. Migraine headache accounts for 1.4% of all neurological and mental disorders.2 It was reported that the estimated lifetime prevalence of migraine ranged 12%-18%.3 Chronic migraine is defined by the International Classification of Headache Disorders - ICHD-3 as having headaches for ≥ 15 days per month, for ≥ 3 months , which ≥ 8 days/month are linked to migraine. Chronic migraine affects around 1%-4% of the population and chronic tension-type headache about 2.2%.4 Approximately 25%-50% of those affected also have medication overuse headache, which has a population prevalence of 1%.5 Chronic headache is a severely disabling long-term condition, with higher symptom ,frequency and severity than episodic headache.6


Clinical Trial Description

Nowadays, headache has been considered as one of the top global disabling medical conditions.1 Migraine is an important type of headache, and one of the chronic multifaceted neuro-inflammatory disorders.2 It is characterized by recurrent throbbing headache pain that typically affects one side of the head, and is often accompanied by nausea and disturbed vision. Migraine headache accounts for 1.4% of all neurological and mental disorders.2 It was reported that the estimated lifetime prevalence of migraine ranged 12%-18%.3 Chronic migraine is defined by the International Classification of Headache Disorders - ICHD-3 as having headaches for ≥ 15 days per month, for ≥ 3 months , which ≥ 8 days/month are linked to migraine. Chronic migraine affects around 1%-4% of the population and chronic tension-type headache about 2.2%.4 Approximately 25%-50% of those affected also have medication overuse headache, which has a population prevalence of 1%.5 Chronic headache is a severely disabling long-term condition, with higher symptom ,frequency and severity than episodic headache.6 Diagnostic criteria of chronic migraine according to ICHD(7) Description: Headache occurring on 15 or more days/month for more than 3 months, which, on at least 8 days/month, has the features of migraine headache. Diagnostic criteria: A. Headache (migraine-like or tension-type-like1) on ≥15 days/month for >3 months, and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura C. On ≥8 days/month for >3 months, fulfilling any of the following: 1. criteria C and D for 1.1 Migraine without aura 2. criteria B and C for 1.2 Migraine with aura 3. elieved by the patient to be migraine at onset and relieved by a triptan or ergot derivative D Not better accounted for by another ICHD-3 diagnosis. Episodic migraine (EM) is characterized by those with migraine who have 0 to 14 headache days per month, while chronic migraine (CM) is characterized by 15 or more headache days per month. The relationship between EM and CM is complex. EM progresses to CM at the rate of 2.5% per year [8], and CM often remits to EM (2-year transition rate of 26%) [9]. Several factors have been associated with migraine chronification (predictors) ; such as age: - Age *Sex *Presence of depression *Presence of anxiety - sleep disorder *obesity *medication compliance *medication overuse - coffee * low income *allodynia *other pain disordes comorbidities. Our aims were to identify factors that predict prognosis in patients with chronic Migraine. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05079659
Study type Observational
Source Assiut University
Contact mostafa omar, master
Phone 01050659948
Email mostafa189199400@yahoo.com
Status Recruiting
Phase
Start date January 1, 2021
Completion date August 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT05720819 - Biofeedback-VR for Treatment of Chronic Migraine N/A
Not yet recruiting NCT06428838 - Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context Phase 3
Recruiting NCT05517200 - Pilot Study for a Machine Learning Test for Migraine
Recruiting NCT05891808 - miR-155 Expression in Episodic and Chronic Migraine
Completed NCT02514148 - Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients N/A
Enrolling by invitation NCT02291380 - A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine Phase 3
Withdrawn NCT02122744 - RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine N/A
Completed NCT02122237 - Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial Phase 3
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT01709708 - Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine Phase 4
Completed NCT01741246 - Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging N/A
Completed NCT01090050 - Treximet in the Treatment of Chronic Migraine Phase 4
Recruiting NCT03507400 - Introvision for Migraine and Headaches N/A
Completed NCT04161807 - Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine N/A
Completed NCT03175263 - OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain N/A
Withdrawn NCT04353505 - Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache Phase 1
Completed NCT01667250 - Non-Invasive Neurostimulation for the Prevention of Chronic Migraine N/A
Completed NCT01700387 - A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency Phase 4
Not yet recruiting NCT01135784 - Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache Phase 2
Completed NCT01496950 - Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine Phase 1